Compare iShares MSCI South Korea ETF (EWY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Revvity Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.38 (market cap $26.25B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: iShares MSCI South Korea ETF is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and Revvity Inc for 12 Days on average.
| EWY | RVTY | |
|---|---|---|
Market Cap | $26.25B | $16.98B |
Volume | 19,056,075 | 1,456,900 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $157.36 |
52-Week Low | $80.72 | $82.26 |
Typical Hold Time | 47 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $177.18, down 3.56% amid broad Asian market weakness driven by rising oil prices and global bond yields. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights South Korea's KOSPI volatility, with semiconductor stocks facing pressure despite strong AI demand fundamentals and corporate earnings resilience.
The outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to memory cycle trends. While AI infrastructure spending provides long-term growth potential, near-term risks include rising borrowing costs, oil price volatility, and geopolitical tensions. The ETF's heavy technology weighting creates both opportunity and vulnerability to sector-specific headwinds.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
